Vertosa Announces U.S. Patent & Engages Emery Pharma To Help Develop Cannabis-Infused Products

3 min readPublished On: July 30th, 2021By

OAKLAND–Vertosa, a science-first cannabis company that creates effective and reliable active ingredients for infused products, announced the United States patent for one of its core emulsion formulas. Validated by two years of use in the market, the now patented formula is part of a growing portfolio of intellectual property for Vertosa and its brand partners.

In addition, Vertosa, in partnership with Emery Pharma, an accredited third party full-service contract research laboratory, will conduct a series of Pharmacokinetic (PK) studies that explore the bioavailability of emulsified CBD, THC, and other compounds derived from the cannabis plant with a specific focus on the efficacy of various product formats made with cannabis distillate versus cannabis emulsion.

(Image: Pharmacokinetic Diagram)

The CBD study results will be published this summer. As cannabis legalization expands worldwide, and influential markets like New York emerge, Vertosa’s patented technology and pharmaceutical knowledge will help an even broader range of companies achieve a targeted experience for consumers and accelerate products to market.

(Image: Benjamin Larson CEO of Vertosa and main image)

“Vertosa’s patent is a key indicator that the U.S. cannabis industry can continue to mature by creating intellectual property that wins the trust of food and beverage brands, both large and small,” said Ben Larson, Vertosa CEO.

“Our partnership with Emery Pharma exemplifies our deep commitment to using pharmaceutical knowledge to produce the safest, most effective and reliable fast-acting ingredients on the market and will be a key component as we expand our patent portfolio and knowledge of cannabis consumption.”


Vertosa was issued a U.S. patent May 25, 2021 for a core emulsion formula it has been using since 2019 with brands such as Vita Coco EU, WUNDER, Artet and Calexo. Vertosa’s state-of-the-art, water-dispersible solution is far more bioavailable than conventional oils, which means consumers benefit from a consistent experience and more rapid onset, allowing for greater control and metered dosing. Vertosa’s patented technology, and the company’s portfolio of emulsions, are also the most proven and stable solutions on the market, especially as it pertains to aluminum can stability. This means the solutions do not experience separation, sedimentation, or droplet size increases and have been lab tested for a variety of manufacturing processes.


Companies not only sell products, they also sell trust. As cannabis consumption continues to expand into the mainstream, companies will seek ways to further improve infused products that offer a safe and reliable experience for consumers.

Vertosa’s partnership with Emery Pharma will examine the bioavailability of CBD, THC and other cannabis-derived compounds as it pertains to the efficacy of gummies and beverages made with cannabis distillate versus cannabis emulsion.

The PK studies are expected to provide brands with the data needed to effectively bring products to market. Once available, Vertosa will actively share the research data with other operators to ensure the growth and sophistication of the cannabis industry as a whole.

Emery Pharma will work with the Vertosa team to conduct multiple PK studies in order to better understand how CBD and THC is absorbed into the body and metabolized. This will strengthen Vertosa’s understanding of its products and will ultimately enhance the safety and efficacy of the company’s formulations.

“We are impressed by Vertosa’s commitment to delivering a safe and effectiveeffective cannabis formulation to the market-place,” said Ph.D., Emery Pharma President and CEO.

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News